ADPT Q2 2018 Earnings Report — Adaptive Biotechnologies Corporation Revenue & Financial Results | Market Cap Arena

Adaptive Biotechnologies CorporationADPT

Q2 2018 Earnings

Reported June 29, 2018

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	Q2 2018	Q1 2018	Q2 2017	QoQ Change	YoY Change
Revenue	$12M	$10M	—	19.1%	—
Op. Income	-$13M	-$13M	—	-1.3%	—
Gross Margin	56.4%	58.9%	—	-2.5pp	—
Net Margin	-108.0%	-127.5%	—	19.5pp	—
EPS (Diluted)	$-0.12	$-0.12	—	0.0%	—
Free Cash Flow	-$10M	-$7M	—	-50.7%	—

Income Statement

Item	Amount
REVENUE	$12M
Cost of Revenue	$5M
GROSS PROFIT	$7M
R&D Expenses	$9M
Selling & Marketing	$5M
General & Administrative	$5M
SG&A Expenses	$10M
Other Expenses	$424.0K
Operating Expenses	$20M
Cost & Expenses	$25M
OPERATING INCOME	-$13M
Interest Income	$820.0K
Interest Expense	$0
Other Income/Expenses	$820.0K
INCOME BEFORE TAX	-$12M
Income Tax Expense	$0
Net Income from Continuing Ops	-$12M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	-$12M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	-$12M
D&A	$1M
EBIT	-$13M
EBITDA	-$12M
EPS	-$0
EPS Diluted	-$0

Cash Flow Statement

Item	Amount
Net Income	-$12M
Depreciation & Amortization	$1M
Stock-Based Compensation	$2M
Deferred Income Tax	-$338.0K
Other Non-Cash Items	$2.0K
Change in Working Capital	-$176.0K
OPERATING CASH FLOW	-$9M
Capital Expenditure	-$1M
Acquisitions (Net)	$0
Purchases of Investments	-$30M
Sales/Maturities of Investments	$35M
Other Investing Activities	$19.0K
NET CASH FROM INVESTING	$5M
Net Debt Issuance	$0
Common Stock Repurchased	$0
Common Dividends Paid	$0
Other Financing Activities	$446.0K
NET CASH FROM FINANCING	$446.0K
FREE CASH FLOW	-$10M
Net Change in Cash	-$4M